Author: Willem van Lawick

Amsterdam, The Netherlands, June 30, 2016 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative T-cell immunotherapy treatments for blood cancers and inherited blood disorders, today announces that its lead product, ATIR101™, has been granted an expansion to its existing Orphan Drug Designation… Continue reading Kiadis Pharma’s Orphan Drug Designation for ATIR101™ further expanded to include treatment in a hematopoietic stem cell transplantation

PCT will supply study medication for the US part of Kiadis Pharma’s Phase III clinical trial with ATIR101™ Amsterdam, The Netherlands, June 21, 2016 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative T-cell immunotherapy treatments for blood cancers and inherited blood disorders,… Continue reading Kiadis Pharma Appoints PCT as its Contract Manufacturing Organization in the United States

~ Regulatory strategy update ~ Amsterdam, The Netherlands, June 2, 2016, – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative T-cell immunotherapy treatments for blood cancers and inherited blood disorders, today announces a regulatory strategy update that, based on positive Phase II data,… Continue reading Kiadis Pharma announces its decision to file for marketing authorization with the European Medicines Agency (EMA) for ATIR101™ in blood cancers

SAN RAFAEL, Calif., May 31, 2016 (GLOBE NEWSWIRE) — BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that it has withdrawn its Kyndrisa™ (drisapersen) Marketing Authorization Application (MAA) from the European Medicines Agency (EMA) following discussions at the May 2016 Committee for Medicinal Products for Human Use (CHMP) meeting. Those discussions clearly indicated that the CHMP intended… Continue reading BioMarin Announces Withdrawal of Market Authorization Application for Kyndrisa™ (drisapersen) in Europe

Amsterdam, The Netherlands, April 15, 2016 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative T-cell immunotherapy treatments for blood cancers and inherited blood disorders, today announces its audited annual results for the year ended 31 December 2015, which have been prepared in… Continue reading Kiadis Pharma announces Annual Results for the year ended 31 December 2015